<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37097524</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0755</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Immunologic research</Title><ISOAbbreviation>Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Potential role of EBV and Toll-like receptor 9 ligand in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>698</StartPage><EndPage>708</EndPage><MedlinePgn>698-708</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12026-023-09380-6</ELocationID><Abstract><AbstractText>SLE is a multisystem autoimmune disease characterized by multiple immunological abnormalities including production of autoantibodies. While the etiology of SLE is largely unknown, it is generally accepted that both genetic and environmental factors contribute to disease risk and immune dysregulation. Production of IFN-&#x3b1; is important for protecting the host against infections; however, over stimulation of innate immune pathways can induce autoimmune disease. Environmental factors, particularly Epstein-Barr virus (EBV), have been proposed to play an important role in SLE disease. Improper engagement of Toll-like receptor (TLR) pathways by endogenous or exogenous ligands may lead to the initiation of autoimmune responses and tissue injury. EBV is shown to be a potent stimulant of IFN-&#x3b1; by TLR signaling cascades. Given the highlighted role of IFN-&#x3b1; in SLE pathogenesis and potential role of EBV infection in this disease, the present study is aimed at exploring the in vitro effects of EBV infection and CPG (either alone or in combination) on IFN-&#x3b1;. We also examined the expression level of CD20 and BDCA-4 and CD123 in PBMCs in 32 SLE patients and 32 healthy controls. Our results showed PBMCs treated with CPG-induced higher levels of IFN-&#x3b1; and TLR-9 gene expression fold change compared to cells treated with either EBV or EBV-CPG. Moreover, PBMCs treated with CPG produced significantly higher IFN-&#x3b1; concentration in supernatant compared to cells treated with EBV but not EBV-CPG. Our results further highlight the potential role of EBV infection and TLRs in SLE patients although more studies are warranted to ascertain the global imprint that EBV infection can have on immune signature in patients with SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Izadi</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, 14155, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najfizadeh</LastName><ForeName>Sayed Reza</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Rheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nejati</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, 14155, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>TeimooriRad</LastName><ForeName>Majid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, 14155, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahmahmoodi</LastName><ForeName>Shohreh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, 14155, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirazi</LastName><ForeName>Frough Golsaz</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shokri</LastName><ForeName>Fazel</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marashi</LastName><ForeName>Sayed Mahdi</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-7754-2674</Identifier><AffiliationInfo><Affiliation>Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, 14155, Iran. m-marashi@tums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Immunol Res</MedlineTA><NlmUniqueID>8611087</NlmUniqueID><ISSNLinking>0257-277X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051217">Toll-Like Receptor 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051217" MajorTopicYN="N">Toll-Like Receptor 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051199" MajorTopicYN="N">Toll-Like Receptor 7</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CPG</Keyword><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">IFN-&#x3b1;</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37097524</ArticleId><ArticleId IdType="doi">10.1007/s12026-023-09380-6</ArticleId><ArticleId IdType="pii">10.1007/s12026-023-09380-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol. 2006;92:1&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17145301</ArticleId><ArticleId IdType="doi">10.1016/S0065-2776(06)92001-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallin H, Blomberg S, Alm G, Cederblad B, R&#xf6;nnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-&#x3b1;) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol. 1999;115(1):196.</Citation><ArticleIdList><ArticleId IdType="pubmed">9933442</ArticleId><ArticleId IdType="pmc">1905199</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2249.1999.00772.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson A, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9(9):664&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11199920</ArticleId><ArticleId IdType="doi">10.1191/096120300674499064</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther. 2003;5(2):68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">12718746</ArticleId><ArticleId IdType="pmc">165035</ArticleId><ArticleId IdType="doi">10.1186/ar625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamen DL. Environmental influences on systemic lupus erythematosus expression. Rheum Dis Clin. 2014;40(3):401&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2014.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1228&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19838195</ArticleId><ArticleId IdType="pmc">2925843</ArticleId><ArticleId IdType="doi">10.1038/ng.468</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016;28(5):497.</Citation><ArticleIdList><ArticleId IdType="pubmed">27428889</ArticleId><ArticleId IdType="pmc">4965307</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000318</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev. 2009;8(4):337&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19167523</ArticleId><ArticleId IdType="pmc">2822456</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2008.12.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi S, Najafizadeh SR, Nejati A, Teymoori-Rad M, Shahmahmoodi S, Shirazi FG, et al. Overall status of Epstein-Barr virus infection, IFN-a, and TLR-7/9 in patients with systemic lupus erythematous. Iran J Immunol. 2021;18(3):230.</Citation><ArticleIdList><ArticleId IdType="pubmed">34596588</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon UY, Park SJ, Oh ST, Kim W-U, Park S-H, Lee S-H, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004;6(4):R295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15225364</ArticleId><ArticleId IdType="pmc">464871</ArticleId><ArticleId IdType="doi">10.1186/ar1181</ArticleId></ArticleIdList></Reference><Reference><Citation>Truszewska A, Wirkowska A, Gala K, Truszewski P, Krzemie&#x144;-Ojak &#x141;, Mucha K, et al. EBV load is associated with cfDNA fragmentation and renal damage in SLE patients. Lupus. 2021;30(8):1214&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33866897</ArticleId><ArticleId IdType="doi">10.1177/09612033211010339</ArticleId></ArticleIdList></Reference><Reference><Citation>James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman T, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Investig. 1997;100(12):3019&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9399948</ArticleId><ArticleId IdType="pmc">508514</ArticleId><ArticleId IdType="doi">10.1172/JCI119856</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, et al. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity. 2005;23(5):465&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286015</ArticleId><ArticleId IdType="pmc">7111074</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2005.09.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, et al. EBV stimulates TLR-and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur J Immunol. 2013;43(1):147&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">22996354</ArticleId><ArticleId IdType="doi">10.1002/eji.201242552</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiducci C, Coffman R, Barrat F. Signalling pathways leading to IFN-&#x3b1; production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med. 2009;265(1):43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19093959</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2796.2008.02050.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning S. Innate immune modulation in EBV infection. Herpesviridae. 2011;2(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21429244</ArticleId><ArticleId IdType="pmc">3063194</ArticleId><ArticleId IdType="doi">10.1186/2042-4280-2-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiola S, Gosselin D, Takada K, Gosselin J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol. 2010;185(6):3620&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">20713890</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.0903736</ArticleId></ArticleIdList></Reference><Reference><Citation>Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. Recognition of herpesviruses by the innate immune system. Nat Rev Immunol. 2011;11(2):143&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">21267015</ArticleId><ArticleId IdType="pmc">3686362</ArticleId><ArticleId IdType="doi">10.1038/nri2937</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastav M, Niewold TB. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol. 2013;4:319.</Citation><ArticleIdList><ArticleId IdType="pubmed">24109483</ArticleId><ArticleId IdType="pmc">3791549</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2013.00319</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan TE, Roman RM, Rudenga BJ, Holers VM, Craft JE. Epstein-Barr virus promotes interferon-&#x3b1; production by plasmacytoid dendritic cells. Arthritis Rheum. 2010;62(6):1693&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">20178121</ArticleId><ArticleId IdType="pmc">2885535</ArticleId><ArticleId IdType="doi">10.1002/art.27408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentz GL, Shackelford J, Pagano JS. Epstein-Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation. J Virol. 2012;86(22):12251&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22951831</ArticleId><ArticleId IdType="pmc">3486478</ArticleId><ArticleId IdType="doi">10.1128/JVI.01407-12</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum: Off J Am Coll Rheumatol. 1997;40(5):809&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400506</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokri F, Mageed R, Maziak B, Jefferis R. Expression of VHIII-associated cross-reactive idiotype on human B lymphocytes. Association with staphylococcal protein A binding and Staphylococcus aureus Cowan I stimulation. J Immunol. 1991;146(3):936&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">1846385</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.146.3.936</ArticleId></ArticleIdList></Reference><Reference><Citation>Teymoori-Rad M, Sahraian MA, Mokhtariazad T, Nejati A, Mozdabadi RSK, Amiri MM, et al. Illuminating the in vitro effects of Epstein-Barr virus and vitamin D on immune response in multiple sclerosis patients. J Neurovirol. 2021;27(2):260&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">33666884</ArticleId><ArticleId IdType="doi">10.1007/s13365-021-00951-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C T method. Nat Protoc. 2008;3(6):1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId><ArticleId IdType="doi">10.1038/nprot.2008.73</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nz C, L&#xfc;nemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol. 2009;9(4):246&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">19319143</ArticleId><ArticleId IdType="pmc">2854652</ArticleId><ArticleId IdType="doi">10.1038/nri2527</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe5;ve U, Alm GV, R&#xf6;nnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-&#x3b1; inducer. J Immunol. 2000;165(6):3519&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">10975873</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.165.6.3519</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallin H, Perers A, Alm GV, R&#xf6;nnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-&#x3b1; inducer in systemic lupus erythematosus. J Immunol. 1999;163(11):6306&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10570325</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.163.11.6306</ArticleId></ArticleIdList></Reference><Reference><Citation>Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003;19(6):837&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">14670301</ArticleId><ArticleId IdType="doi">10.1016/S1074-7613(03)00323-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol. 1998;16(3):289&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9631751</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente RM, Ehlers E, Xu D, Ahmad H, Steadman A, Blasnitz L, et al. Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1. PLoS ONE. 2012;7(8):e43317.</Citation><ArticleIdList><ArticleId IdType="pubmed">22952664</ArticleId><ArticleId IdType="pmc">3432040</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0043317</ArticleId></ArticleIdList></Reference><Reference><Citation>Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol. 2001;167(4):2361&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11490026</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.167.4.2361</ArticleId></ArticleIdList></Reference><Reference><Citation>Folzenlogen D, Hofer M, Leung D, Freed J, Newell M. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol. 1997;83(3):199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">9175908</ArticleId><ArticleId IdType="doi">10.1006/clin.1997.4353</ArticleId></ArticleIdList></Reference><Reference><Citation>Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Investig. 2003;112(10):1506&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14617752</ArticleId><ArticleId IdType="pmc">259134</ArticleId><ArticleId IdType="doi">10.1172/JCI200319301</ArticleId></ArticleIdList></Reference><Reference><Citation>Huck S, Corre RL, Youinou P, Zouali M. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity. 2001;33(3):213&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683380</ArticleId><ArticleId IdType="doi">10.3109/08916930109008048</ArticleId></ArticleIdList></Reference><Reference><Citation>Liossis S, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Investig. 1996;98(11):2549&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">8958217</ArticleId><ArticleId IdType="pmc">507712</ArticleId><ArticleId IdType="doi">10.1172/JCI119073</ArticleId></ArticleIdList></Reference><Reference><Citation>Liossis S-NC, Solomou EE, Dimopoulos M-A, Panayiotidis P, Mavrikakis MM, Sfikakis PP. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Invest Med. 2001;49(2):157&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="doi">10.2310/6650.2001.34042</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W, Hamilton A, Deapen D, Mack T, Horwitz D. Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells. Lupus. 1999;8(4):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10413208</ArticleId><ArticleId IdType="doi">10.1191/096120399678847768</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos G, Magrath I, Balow J. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol. 1983;131(4):1797&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">6311898</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.131.4.1797</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017;214(5):1547&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">28420733</ArticleId><ArticleId IdType="pmc">5413335</ArticleId><ArticleId IdType="doi">10.1084/jem.20161451</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Gunnarsson I, Dorschner J, Eketj&#xe4;ll S, Zickert A, Niewold TB, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107.</Citation><ArticleIdList><ArticleId IdType="pubmed">31036046</ArticleId><ArticleId IdType="pmc">6489203</ArticleId><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok S-K, Lee J-Y, Park S-H, Cho M-L, Min S-Y, Park S-H, et al. Dysfunctional interferon-&#x3b1; production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(2):R29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18321389</ArticleId><ArticleId IdType="pmc">2453773</ArticleId><ArticleId IdType="doi">10.1186/ar2382</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008;19(1):3&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">18248767</ArticleId><ArticleId IdType="pmc">2277216</ArticleId><ArticleId IdType="doi">10.1016/j.cytogfr.2007.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg S, Eloranta M-L, Cederblad B, Nordlind K, Alm G, R&#xf6;nnblom L. Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosus. Lupus. 2001;10(7):484&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11480846</ArticleId><ArticleId IdType="doi">10.1191/096120301678416042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton JA, Hsu H-C, Mountz JD. Role of production of type I interferons by B cells in the mechanisms and pathogenesis of systemic lupus erythematosus. Discov Med. 2018;25(135):21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29466691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cederblad B, Blomberg S, Vallin H, Perers A, Alm G, R&#xf6;nnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-&#x3b1;-producing cells. J Autoimmun. 1998;11(5):465&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9802930</ArticleId><ArticleId IdType="doi">10.1006/jaut.1998.0215</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanarajasingam U, Muppirala AN, Jensen MA, Ghodke-Puranik Y, Dorschner JM, Vsetecka DM, et al. Type I interferon predicts an alternate immune system phenotype in systemic lupus erythematosus. ACR Open Rheumatol. 2019;1(8):499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">31777831</ArticleId><ArticleId IdType="pmc">6858011</ArticleId><ArticleId IdType="doi">10.1002/acr2.11073</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-&#x3b1;/&#x3b2;-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159(1):237&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438470</ArticleId><ArticleId IdType="pmc">1850412</ArticleId><ArticleId IdType="doi">10.1016/S0002-9440(10)61689-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-and pH-dependent manner. Eur J Immunol. 2004;34(9):2541&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15307186</ArticleId><ArticleId IdType="doi">10.1002/eji.200425218</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;seke S, Grage-Griebenow E, Wagner A, Gehlhar K, Bufe A. Differential expression of IFN-&#x3b1; subtypes in human PBMC: evaluation of novel real-time PCR assays. J Immunol Methods. 2003;276(1&#x2013;2):207&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738374</ArticleId><ArticleId IdType="doi">10.1016/S0022-1759(03)00072-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yang J, Chu Y, Xue Y, Xuan D, Zheng S, et al. T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus. PLoS ONE. 2014;9(2):e88441.</Citation><ArticleIdList><ArticleId IdType="pubmed">24551101</ArticleId><ArticleId IdType="pmc">3925141</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0088441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Ben ERR, do Prado CH, Baptista TSA, Bauer ME, Staub HL. Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4+ CD25+ Foxp3+ Treg and CD3&#x2013;CD19+ B cells. Revista Brasileira de Reumatologia (English Edition). 2014;54(3):241&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rbre.2013.09.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Younesi V, Nikzamir H, Yousefi M, Khoshnoodi J, Arjmand M, Rabbani H, et al. Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes. Microbiol Immunol. 2010;54(9):534&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">20840152</ArticleId><ArticleId IdType="doi">10.1111/j.1348-0421.2010.00248.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gujer C, Murer A, M&#xfc;ller A, Vanoaica D, Sutter K, Jacque E, et al. Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile. Blood Adv. 2019;3(7):1129&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">30952679</ArticleId><ArticleId IdType="pmc">6457222</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2018025536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlaepfer E, Audig&#xe9; A, von Beust B, Manolova V, Weber M, Joller H, et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol. 2004;78(22):12344&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15507621</ArticleId><ArticleId IdType="pmc">525063</ArticleId><ArticleId IdType="doi">10.1128/JVI.78.22.12344-12354.2004</ArticleId></ArticleIdList></Reference><Reference><Citation>Luganini A, Caposio P, Landolfo S, Gribaudo G. Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry. Antimicrob Agents Chemother. 2008;52(3):1111&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18180342</ArticleId><ArticleId IdType="pmc">2258505</ArticleId><ArticleId IdType="doi">10.1128/AAC.00987-07</ArticleId></ArticleIdList></Reference><Reference><Citation>James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001;44(5):1122&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352244</ArticleId><ArticleId IdType="doi">10.1002/1529-0131(200105)44:5&lt;1122::AID-ANR193&gt;3.0.CO;2-D</ArticleId></ArticleIdList></Reference><Reference><Citation>Iskra S, Kalla M, Delecluse H-J, Hammerschmidt W, Moosmann A. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J Virol. 2010;84(7):3612&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">20089650</ArticleId><ArticleId IdType="pmc">2838115</ArticleId><ArticleId IdType="doi">10.1128/JVI.01400-09</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsd&#xf6;rfer B, Giese T, et al. Quantitative expression of Toll-like receptor 1&#x2013;10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168(9):4531&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11970999</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.168.9.4531</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol. 2005;174(11):6599&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15905498</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.174.11.6599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>